Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ 30.4 Cr.
- Current Price ₹ 33.0
- High / Low ₹ 78.5 / 25.4
- Stock P/E
- Book Value ₹ 15.9
- Dividend Yield 0.00 %
- ROCE -25.1 %
- ROE -81.8 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 35.8%
- Company has a low return on equity of -19.6% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
0 | 243 | 191 | 212 | 151 | 75 | |
0 | 235 | 178 | 205 | 143 | 91 | |
Operating Profit | -0 | 8 | 13 | 8 | 7 | -16 |
OPM % | 3% | 7% | 4% | 5% | -22% | |
0 | 0 | 0 | 0 | 0 | 2 | |
Interest | 0 | 3 | 2 | 3 | 5 | 4 |
Depreciation | 0 | 2 | 2 | 2 | 3 | 2 |
Profit before tax | -0 | 4 | 9 | 2 | 0 | -21 |
Tax % | 0% | 56% | 29% | 38% | -183% | -3% |
-0 | 2 | 7 | 1 | 1 | -20 | |
EPS in Rs | -0.24 | 1.93 | 7.20 | 1.36 | 1.12 | -21.90 |
Dividend Payout % | 0% | 0% | 14% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -27% |
TTM: | -50% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -2656% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -18% |
1 Year: | -47% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -7% |
3 Years: | -20% |
Last Year: | -82% |
Balance Sheet
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Equity Capital | 0.41 | 9 | 9 | 9 | 9 | 9 |
Reserves | -0 | 17 | 24 | 24 | 26 | 5 |
0 | 12 | 27 | 31 | 44 | 40 | |
0 | 70 | 74 | 51 | 38 | 40 | |
Total Liabilities | 0 | 109 | 133 | 116 | 117 | 95 |
0 | 20 | 21 | 27 | 27 | 25 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 |
0 | 89 | 112 | 89 | 90 | 69 | |
Total Assets | 0 | 109 | 133 | 116 | 117 | 95 |
Cash Flows
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
0 | 27 | 8 | -10 | -11 | 11 | |
0 | -8 | -4 | -7 | 0 | -3 | |
0 | 19 | 12 | 0 | 11 | -8 | |
Net Cash Flow | 0 | 38 | 16 | -16 | -0 | 0 |
Ratios
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Debtor Days | 64 | 69 | 60 | 77 | 64 | |
Inventory Days | 73 | 109 | 98 | 158 | 260 | |
Days Payable | 114 | 161 | 74 | 103 | 175 | |
Cash Conversion Cycle | 23 | 17 | 84 | 131 | 150 | |
Working Capital Days | 28 | 28 | 66 | 126 | 139 | |
ROCE % | 34% | 23% | 9% | 7% | -25% |
Documents
Announcements
-
Disclosure Under Regulation 7(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015 - Mr. Gaddam Balaji, Promoter
30 Jun - Promoter Gaddam Balaji disclosed sale of shares under SEBI insider trading regulations on June 27, 2025.
-
Disclosure Under Regulation 7(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015 - Ms. Alluri Anantha Laxmi, Promoter
30 Jun - Promoter Alluri Anantha Laxmi disclosed sale of shares under SEBI insider trading regulations.
-
Disclosure Under Regulation 7(2) Of The SEBI (Prohibition Of Insider Trading) Regulations, 2015 - Mr. Satyanarayana Raju Bhupathiraju, Promoter
30 Jun - Promoter Satyanarayana Raju Bhupathiraju disclosed sale of shares as per SEBI insider trading rules.
- Closure of Trading Window 30 Jun
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 30 Jun
Product Profile:
a) API Intermediates:[1] Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine
b) Fine Chemicals and Reagents:[2] IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, Aminouracil, etc.